심근염 질환 시장 규모는 향후 몇 년 동안 높은 성장세를 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 정부 지원 및 정책, 표적 치료제의 가용성, 임상시험의 확대, 의료 인프라 개선, 진화하는 치료 지침에 의해 주도될 수 있습니다. 이 기간의 주요 트렌드에는 CRISPR-Cas9 기술의 발전, 3D 프린팅, AI 기반 예측 분석, 가상현실(VR) 기술, 웨어러블 심전도(ECG) 기기 채택 등이 포함됩니다.
만성 질환의 유병률 증가는 심근염 질환 시장의 성장을 견인할 것으로 예상됩니다. 만성 질환은 1년 이상 지속되는 장기적인 건강 상태로, 지속적인 의료 관리, 생활 습관 조정 또는 치료가 필요한 경우가 많습니다. 만성 질환의 증가는 인구 고령화, 앉아서 생활하는 생활 방식, 잘못된 식습관, 비만율 증가, 환경 오염 물질에 대한 노출 증가 등의 요인에 기인합니다. 심장 근육에 영향을 미치는 염증성 질환인 심근염은 장기적인 치료가 필요하고 심혈관 건강에 영향을 미치는 심부전, 부정맥, 심근증과 같은 합병증을 유발하여 만성 건강 문제를 일으킬 수 있습니다. 예를 들어, 2024년 9월 영국의 심혈관 연구 자선단체인 영국심장재단이 발표한 자료에 따르면 영국에서는 약 760만 명의 사람들이 심장 및 순환계 질환의 영향을 받고 있는 것으로 나타났습니다. 이 중 남성이 약 400만 명, 여성이 360만 명입니다. 이러한 질환은 영국 전체 사망의 약 27%를 차지하며, 매년 17만 명 이상이 사망하는데 이는 하루에 480명, 즉 3분마다 한 명씩 사망하는 것과 같습니다. 따라서 만성 질환의 유병률 증가는 심근염 질환 시장의 성장을 촉진하고 있습니다.
심근염 시장의 주요 기업은 치료 옵션을 확대하고 환자 치료 결과를 개선하기 위해 신약에 대한 규제 승인을 우선시하고 있습니다. 규제 승인은 정부 또는 규제 기관이 의약품, 의료기기 또는 치료법을 대중에게 판매하고 활용할 수 있도록 부여하는 공식적인 승인입니다. 예를 들어, 2022년 5월 캐나다에 본사를 둔 제약 회사인 Cardiol Therapeutics는 재발성 심낭염에 대한 CardiolRx의 다기관 2상 오픈 라벨 파일럿 연구에 대한 FDA 임상시험용 신약(IND) 승인을 받았다고 발표했습니다. 이 연구는 곧 시작될 예정인 급성 심근염에 대한 다국가 임상 2상 시험과 함께 진행될 예정입니다. 두 연구 모두 심혈관 질환에 대한 혁신적인 항염증 치료법을 개발하는 데 초점을 맞추고 있습니다. 또한 CardiolRx는 재발성 심낭염과 급성 심근염 모두에 대해 희귀의약품으로 지정되어 이러한 질환을 해결할 수 있는 잠재력을 인정받았습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 심근염 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계의 심근염 시장 : 성장률 분석
- 세계 심근염 시장 실적 : 규모와 성장(2019-2024년)
- 세계의 심근염 시장 예측 : 규모와 성장(2024-2029년, 2034년)
- 세계의 심근염 총 시장 규모(TAM)
제6장 시장 세분화
- 세계의 심근염 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 급성 심근염
- 만성 심근염
- 림프구 심근염
- 세계의 심근염 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 약물
- 수술
- 기타 치료법
- 세계의 심근염 시장 : 진단별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 혈액 검사
- 영상 검사
- 심장 카테터 검사
- 심근 생검
- 기타 진단
- 세계의 심근염 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 병원 약국
- 소매 약국
- 온라인 약국
- 기타 유통 채널
- 세계의 심근염 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 전문 클리닉
- 홈케어
- 기타 최종 사용자
- 세계의 심근염 시장 : 급성 심근염 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 바이러스성 심근염
- 세균성 심근염
- 진균성 심근염
- 세계의 심근염 시장 : 만성 심근염 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 자가면역성 심근염
- 만성 활동성 심근염
- 만성 염증성 심근염
- 세계의 심근염 시장 : 림프성 심근염 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 특발성 림프성 심근염
- 약물 유발성 림프성 심근염
- 바이러스 감염 관련 림프성 심근염
제7장 지역별 및 국가별 분석
- 세계의 심근염 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 심근염 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
- 심근염 시장 : 경쟁 구도
- 심근염 시장 : 기업 프로파일
- Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- Hoffmann-La Roche AG 개요, 제품 및 서비스, 전략 및 재무 분석
- Merck & Co Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- Bristol-Myers Squibb Company 개요, 제품 및 서비스, 전략 및 재무 분석
- AstraZeneca PLC 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Novartis AG
- GlaxoSmithKline plc
- Eli Lilly and Company
- Gilead Sciences Inc.
- Teva Pharmaceutical Industries Ltd.
- Regeneron Pharmaceuticals Inc.
- UCB SA
- Sun Pharmaceutical Industries Ltd.
- Cipla Limited
- Alnylam Pharmaceuticals Inc.
- Sobi(Swedish Orphan Biovitrum AB)
- BridgeBio Pharma Inc.
- Evotec SE
- Cardiol Therapeutics Inc.
- Cantargia AB
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 심근염 시장(2029년) : 새로운 기회를 제공하는 국가
- 심근염 시장(2029년) : 새로운 기회를 제공하는 부문
- 심근염 시장(2029년) : 성장 전략
제36장 부록
HBR
Myocarditis is a rare condition characterized by inflammation of the heart muscle, or myocardium. Treatment approaches focus on reducing inflammation, managing symptoms, and addressing underlying causes such as infections or autoimmune disorders.
The primary types of myocarditis include acute myocarditis, chronic myocarditis, and lymphocytic myocarditis. Acute myocarditis occurs when the heart muscle suddenly becomes inflamed, often due to a viral infection, leading to damage and impaired heart function. Treatment options consist of medications, surgery, and other interventions, while diagnostic methods include blood tests, imaging tests, cardiac catheterization, and heart muscle biopsy. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and other outlets. Key end-users encompass hospitals, specialty clinics, home care services, and additional healthcare providers.
The myocarditis disease market research report is one of a series of new reports from The Business Research Company that provides myocarditis disease market statistics, including myocarditis disease industry global market size, regional shares, competitors with a myocarditis disease market share, detailed myocarditis disease market segments, market trends and opportunities, and any further data you may need to thrive in the myocarditis disease industry. This myocarditis disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The myocarditis disease market size has grown strongly in recent years. It will grow from $1.50 billion in 2024 to $1.61 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth during the historic period can be attributed to the rising prevalence of viral infections, greater awareness of autoimmune diseases, an increased incidence of cardiovascular diseases, advancements in treatment options for heart inflammation, and increased funding for cardiovascular research.
The myocarditis disease market size is expected to see strong growth in the next few years. It will grow to $2.07 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth during the forecast period can be driven by government support and policies, the availability of targeted therapies, the expansion of clinical trials, improved healthcare infrastructure, and evolving treatment guidelines. Key trends in this period include advancements in CRISPR-Cas9 technology, the use of 3D printing, AI-driven predictive analytics, virtual reality (VR) technologies, and the adoption of wearable electrocardiogram (ECG) devices.
The rising prevalence of chronic disorders is expected to drive the growth of the myocarditis disease market. Chronic disorders are long-term health conditions that persist for a year or more, often requiring continuous medical management, lifestyle adjustments, or treatment. The increasing occurrence of chronic disorders is attributed to factors such as aging populations, sedentary lifestyles, poor dietary habits, rising obesity rates, and greater exposure to environmental pollutants. Myocarditis, an inflammatory condition affecting the heart muscle, contributes to chronic health issues by potentially leading to complications such as heart failure, arrhythmias, and cardiomyopathy, which require long-term care and impact cardiovascular health. For instance, in September 2024, according to data published by the British Heart Foundation, a UK-based cardiovascular research charity, approximately 7.6 million people in the UK are affected by heart and circulatory diseases. Of these, around 4 million are males and 3.6 million are females. These conditions account for approximately 27% of all deaths in the UK, leading to over 170,000 deaths annually which is equivalent to 480 deaths per day or one death every three minutes. As a result, the increasing prevalence of chronic disorders is fueling the growth of the myocarditis disease market.
Leading companies in the myocarditis disease market are prioritizing regulatory approvals for new drugs to expand treatment options and improve patient outcomes. Regulatory approvals are formal authorizations granted by governmental or regulatory bodies, allowing drugs, medical devices, or treatments to be marketed and utilized by the public. For example, in May 2022, Cardiol Therapeutics Inc., a Canada-based pharmaceutical company, announced that it had received FDA Investigational New Drug (IND) authorization for a multicenter Phase II open-label pilot study of CardiolRx for recurrent pericarditis. This study will be conducted alongside the company's multinational Phase II trial for acute myocarditis, which is set to commence soon. Both studies focus on developing innovative anti-inflammatory therapies for cardiovascular diseases. Additionally, CardiolRx has been granted orphan drug designation for both recurrent pericarditis and acute myocarditis, underscoring its potential to address these conditions.
In May 2023, Kaiser Permanente, a US-based healthcare company, acquired Geisinger for $5 billion. This acquisition led to the establishment of Risant Health, a nonprofit health system dedicated to expanding value-based care. By integrating community-based health systems, Risant Health aims to improve healthcare accessibility and quality for diverse populations across the United States. Geisinger, a US-based healthcare provider, is actively involved in the management and treatment of myocarditis disease.
Major players in the myocarditis disease market are Pfizer Inc., Hoffmann-La Roche AG, Merck & Co Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Cipla Limited, Alnylam Pharmaceuticals Inc., Sobi (Swedish Orphan Biovitrum AB), BridgeBio Pharma Inc., Evotec SE, Cardiol Therapeutics Inc., and Cantargia AB.
North America was the largest region in the myocarditis disease market in 2024. The regions covered in myocarditis disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the myocarditis disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The myocarditis disease market consists of revenues earned by entities by providing services such as diagnosis and monitoring, pharmacological treatments, hospital care, lifestyle and rehabilitation services, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The myocarditis disease market also includes sales of nonsteroidal anti-inflammatory drugs, corticosteroids, and beta-blockers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Myocarditis Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on myocarditis disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for myocarditis disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The myocarditis disease market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Acute Myocarditis; Chronic Myocarditis; Lymphocytic Myocarditis
- 2) By Treatment: Medication; Surgery; Other Treatments
- 3) By Diagnosis: Blood Tests; Imaging Tests; Cardiac Catheterization; Heart Muscle Biopsy; Others Diagnosis
- 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
- 5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
- Subsegments:
- 1) By Acute Myocarditis: Viral Myocarditis; Bacterial Myocarditis; Fungal Myocarditis
- 2) By Chronic Myocarditis: Autoimmune Myocarditis; Chronic Active Myocarditis; Chronic Inflammatory Myocarditis
- 3) By Lymphocytic Myocarditis: Idiopathic Lymphocytic Myocarditis; Drug-Induced Lymphocytic Myocarditis; Lymphocytic Myocarditis Associated with Viral Infections
- Companies Mentioned: Pfizer Inc.; Hoffmann-La Roche AG; Merck & Co Inc.; Bristol-Myers Squibb Company; AstraZeneca PLC
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Myocarditis Disease Market Characteristics
3. Myocarditis Disease Market Trends And Strategies
4. Myocarditis Disease Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Myocarditis Disease Growth Analysis And Strategic Analysis Framework
- 5.1. Global Myocarditis Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Myocarditis Disease Market Growth Rate Analysis
- 5.4. Global Myocarditis Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Myocarditis Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Myocarditis Disease Total Addressable Market (TAM)
6. Myocarditis Disease Market Segmentation
- 6.1. Global Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Acute Myocarditis
- Chronic Myocarditis
- Lymphocytic Myocarditis
- 6.2. Global Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Medication
- Surgery
- Other Treatments
- 6.3. Global Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Blood Tests
- Imaging Tests
- Cardiac Catheterization
- Heart Muscle Biopsy
- Others Diagnosis
- 6.4. Global Myocarditis Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Other Distribution Channels
- 6.5. Global Myocarditis Disease Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Specialty Clinics
- Homecare
- Other End-Users
- 6.6. Global Myocarditis Disease Market, Sub-Segmentation Of Acute Myocarditis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Viral Myocarditis
- Bacterial Myocarditis
- Fungal Myocarditis
- 6.7. Global Myocarditis Disease Market, Sub-Segmentation Of Chronic Myocarditis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Autoimmune Myocarditis
- Chronic Active Myocarditis
- Chronic Inflammatory Myocarditis
- 6.8. Global Myocarditis Disease Market, Sub-Segmentation Of Lymphocytic Myocarditis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Idiopathic Lymphocytic Myocarditis
- Drug-Induced Lymphocytic Myocarditis
- Lymphocytic Myocarditis Associated with Viral Infections
7. Myocarditis Disease Market Regional And Country Analysis
- 7.1. Global Myocarditis Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Myocarditis Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Myocarditis Disease Market
- 8.1. Asia-Pacific Myocarditis Disease Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Myocarditis Disease Market
- 9.1. China Myocarditis Disease Market Overview
- 9.2. China Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Myocarditis Disease Market
- 10.1. India Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Myocarditis Disease Market
- 11.1. Japan Myocarditis Disease Market Overview
- 11.2. Japan Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Myocarditis Disease Market
- 12.1. Australia Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Myocarditis Disease Market
- 13.1. Indonesia Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Myocarditis Disease Market
- 14.1. South Korea Myocarditis Disease Market Overview
- 14.2. South Korea Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Myocarditis Disease Market
- 15.1. Western Europe Myocarditis Disease Market Overview
- 15.2. Western Europe Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Myocarditis Disease Market
- 16.1. UK Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Myocarditis Disease Market
- 17.1. Germany Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Myocarditis Disease Market
- 18.1. France Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Myocarditis Disease Market
- 19.1. Italy Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Myocarditis Disease Market
- 20.1. Spain Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Myocarditis Disease Market
- 21.1. Eastern Europe Myocarditis Disease Market Overview
- 21.2. Eastern Europe Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Myocarditis Disease Market
- 22.1. Russia Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Myocarditis Disease Market
- 23.1. North America Myocarditis Disease Market Overview
- 23.2. North America Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Myocarditis Disease Market
- 24.1. USA Myocarditis Disease Market Overview
- 24.2. USA Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Myocarditis Disease Market
- 25.1. Canada Myocarditis Disease Market Overview
- 25.2. Canada Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Myocarditis Disease Market
- 26.1. South America Myocarditis Disease Market Overview
- 26.2. South America Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Myocarditis Disease Market
- 27.1. Brazil Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Myocarditis Disease Market
- 28.1. Middle East Myocarditis Disease Market Overview
- 28.2. Middle East Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Myocarditis Disease Market
- 29.1. Africa Myocarditis Disease Market Overview
- 29.2. Africa Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Myocarditis Disease Market Competitive Landscape And Company Profiles
- 30.1. Myocarditis Disease Market Competitive Landscape
- 30.2. Myocarditis Disease Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
31. Myocarditis Disease Market Other Major And Innovative Companies
- 31.1. Novartis AG
- 31.2. GlaxoSmithKline plc
- 31.3. Eli Lilly and Company
- 31.4. Gilead Sciences Inc.
- 31.5. Teva Pharmaceutical Industries Ltd.
- 31.6. Regeneron Pharmaceuticals Inc.
- 31.7. UCB S.A.
- 31.8. Sun Pharmaceutical Industries Ltd.
- 31.9. Cipla Limited
- 31.10. Alnylam Pharmaceuticals Inc.
- 31.11. Sobi (Swedish Orphan Biovitrum AB)
- 31.12. BridgeBio Pharma Inc.
- 31.13. Evotec SE
- 31.14. Cardiol Therapeutics Inc.
- 31.15. Cantargia AB
32. Global Myocarditis Disease Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Myocarditis Disease Market
34. Recent Developments In The Myocarditis Disease Market
35. Myocarditis Disease Market High Potential Countries, Segments and Strategies
- 35.1 Myocarditis Disease Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Myocarditis Disease Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Myocarditis Disease Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
